Nexosome Oncology

Nexos

Nexos Biosciences develops exosome-based drug delivery systems for pharmaceutical companies to enable oral administration of treatments for cancer, inflammation, and metabolic diseases.

LiquidCell Dx

This company develops blood-based liquid biopsy tests for tumor microenvironment profiling to help pharmaceutical companies and clinical partners predict cancer therapy responses.

OXCan

This company develops blood tests using proteomics and machine learning to enable early cancer detection for healthcare providers and patients.

NX Prenatal

This company develops exosome-based blood tests to detect pregnancy complications for physicians and expectant mothers.

Fyr Bio

This company develops liquid biopsy diagnostic tools and biomarkers using extracellular vesicle enrichment technology for healthcare providers and pharmaceutical researchers.

Oncosyne

This company develops patient-derived tumoroid drug screening platforms for pharmaceutical firms and oncologists to improve drug discovery and personalised cancer treatment.

Epiliquid

This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.

Nextera

This company develops antibody therapies and drug targets for pharmaceutical organisations treating cancer, autoimmunity and inflammatory diseases.